Pharmacoeconomic review report : Nitisinone (MDK-Nitisinone) (MendeliKABS inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

• Book

Language:

English

Subjects (All):

• Enzyme inhibitors.

Physical Description:

1 online resource (22 pages) : illustrations

Other Title:

Pharmacoeconomic review report Nitisinone

Place of Publication:

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2018.

Summary:

Nitisinone (MDK-Nitisinone) is an inhibitor of the tyrosine catabolic pathway and is indicated for patients with hereditary tyrosinemia type 1 (HT-1), in combination with dietary restriction of tyrosine and phenylalanine. Nitisinone is available as 2 mg, 5 mg, 10 mg, and 20 mg capsules. The submitted price of nitisinone is based on dose: (2 mg $14.78), 5 mg ( 4.18), 10 mg (

Contents:

• Abbreviations
• Executive Summary
• Background
• Summary of Identified Limitations and Key Results
• Conclusions
• Information on the Pharmacoeconomic Submission
• Summary of the Manufacturer's Pharmacoeconomic Submission
• Manufacturer's Base Case
• Limitations of Manufacturer's Submission
• CADTH Common Drug Review Reanalyses
• Issues for Consideration
• Patient Input
• Appendix 1. Cost Comparison
• Appendix 2. Summary of Key Outcomes
• Appendix 3. Additional Information
• Appendix 4. Summary of Other Health Technology Assessment Reviews of the Drug
• Appendix 5. Reviewer Worksheets
• References.

Notes:

• Description based on publisher supplied metadata and other sources.
• Includes bibliograhical references.